Abstract: The present invention discloses a bi-mode insulated gate transistor, belonging to the technical filed of IGBTs. The bi-mode insulated gate transistor includes a reverse conducting region and a pilot region, wherein the reverse conducting region and the pilot region each include P+ collector regions, a drift region and a MOS cell region, the drift regions are disposed over the P+ collector regions, and the MOS cell regions are disposed over the drift regions; the reverse conducting region further includes N+ collector regions, and the N+ collector regions and the P+ collector regions are distributed alternatively; the pilot region further includes a separation region or a low-doped region, the separation region isolates the P+ collector regions of the pilot region from the P+ collector regions and the N+ collector regions of the reverse conducting region, and the low doped region is disposed over the P+ collector regions of the pilot region.

Abstract: This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID 2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils.

Abstract: This invention provides a fusion protein (FP4) and the code gene, expression method, and clinical application; its goal is to provide a fusion protein, the code gene, and the expression method as well as to take this fusion protein as the active constituent anti-allergic medicine. In addition, the invention provides the sequence of fusion protein attached on SEQ ID 2 and any derivation protein of the fusion protein (FP4) which includes adding or deleting several amino acids of SEQ ID2 as well as increasing or deducing nuclear tides of SEQ ID 1. We designed to cross-link IgE active receptor and an IgG inhibitory receptor by endogens hinge without any extraneous chemical link. This invention fusion protein has function to block the IgE acceptor, moreover fragment of fusion protein has ability to specifically bind to a native IgG inhibitory receptor containing immunoreceptor tyrosine-based inhibitory motif, thereby inhibiting the IgE-driven mediator release from mast cells and basophils.